

FoI request re: biologics and biosimilar prescribing
Ref: 19-JS-2506

Dear,

Thank you for your request for information relating to biologics and biosimilar prescribing.

This was received on 28 May 2019 and has been dealt with under the terms of the Freedom of Information Act 2000.

Please find our responses below:

Request:

I wonder if you can help with regards to a Freedom of Information request I have for Biologics and Biosimilar prescribing. Could you please provide me with following numbers of patients treated in the last 12 months (latest) 12 months possible) with the following drugs for either **Rheumatology, Dermatology and Gastroenterology** departments:

Treatment	Total	Rheumatology	Dermatology	Gastroenterology
Abatacept (Orencia)		≤5		
Adalimumab biosimilar (Amgevita)		47		25
Adalimumab biosimilar (Hulio)				
Adalimumab (Humira)		87	≤5	33
Adalimumab biosimilar (Hyrimoz)		9		10
Adalimumab bioisimilar (Imraldi)				
Apremilast (Otezla)				
Baricitinib (Olumiant)				
Brodalumab (Kyntheum)				
Certolizumab (Cimzia)		≤5		
Dimethyl Fumarate (Skilarence)				
Etanercept (Enbrel)		13		
Etanercept Biosimilar (Benepali)		93		
Etanercept				

Whittington Health NHS Trust

Interim Chair: David Holt Chief Executive: Siobhan Harrington

Biosimilar (Erelzi)				
Golimumab (Simponi)		12		12
Guselkumab (Tremfya)			≤5	
Infliximab (Flixabi)				
Infliximab (Inflectra)				
Infliximab (Remicade)		≤5		20
Infliximab (Remsima)		≤5		82
Ixekizumab (Taltz)				
Rituximab (Mabthera)				
Rituximab Biosimilar (Rixathon)				
Rituximab Biosimilar (Truxima)		42		
Sarilumab (Kevzara)				
Secukinumab (Cosentyx)		37	≤5	
Tildrakizumab (Ilumetri)				
Tocilizumab (Ro Actemra)		6		
Tofacitinib (Xeljanz)				
Ustekinumab (Stelara)		11	32	14
Vedolizumab (Entyvio)				31

Please note that the trust's policy is not to provide patient or staff numbers, where the response is less than or equal to five (≤ 5) as it would potentially allow identification of the individual patient/staff and would therefore be personal data. The trust considers that release of that information would breach GDPR/DPA18 principles on the grounds that it would not be fair in all the circumstances. This information is therefore exempt under section 40 of the FOI Act 2000.


I hope you find this information useful. Please quote the above reference in any further communication on this matter.

Whittington Health NHS Trust

Interim Chair: David Holt Chief Executive: Siobhan Harrington

If you require any further assistance, please do not hesitate to contact me by email or at the address shown below.

Yours sincerely

FOI Coordinator
Freedom of Information Office
Whittington Health
Highgate Wing, Level 5
Magdala Avenue
London, N19 5NF
foi.whitthealth@nhs.net
Whittington Health 

If you are dissatisfied with this response, Whittington Health operates a complaints procedure, details of which can be found below:

FOI Complaints:

In the first instance, write to:

Director Lead for Information Governance

Chief Operating Officer
Jenner Building
Magdala Avenue
London
N19 5NF
020 7288 5255
foi.whitthealth@nhs.net

If you remain dissatisfied with the Trust's response, you may write to:

Information Commissioner's Office

Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF
Telephone: 0303 123 1113 or 01625 545745
www.ico.org.uk

Whittington Health NHS Trust

Interim Chair: David Holt Chief Executive: Siobhan Harrington